TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Caregiver Burden Inventory (CBI)
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Quality of Life [Short Form Health Survey (SF-12)]
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Family Function (Family APGAR)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Overall Survival Time (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Difficulty of catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intra-expert concordance of therapeutic management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronavirus Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean change in ABC-I score (Irritability)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Harris functional hip score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in range of motion of the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in semiquantitative tenderness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary allopregnanolone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: understanding of overall uncertainty of benefit
Endpoint domain: Adverse events/effects
Primary endpoint: understanding of overall uncertainty of harm
Endpoint domain: Adverse events/effects
Primary endpoint: sufficiency of what is known about the effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAD+ mass isotopomers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with positive sIgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change in community systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of seroconverted participants for anti-rotavirus (RV) immunoglobulin A (IgA) antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum anti-RV IgA Ab concentrations expressed as geometric mean concentrations (GMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with unrecognized and underlying myocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brief Pain Inventory -- Interference subscale (BPI-I)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weekly changes of Patient Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline of CCAPS-34 scores to Post-intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline of DASC-21 scores to Post-intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline of CCAPS-34 scores to 10 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline of DASC-21 scores to 10-weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence to Nintedanib
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adverse reactions of the respiratory tract
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse reactions of the skin
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse reactions of the eye
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse reactions of the central nervous system
Endpoint domain: Adverse events/effects
Primary endpoint: Time and Level of Assistance (LoA) to don/doff the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Level of Assistance (LoA) to complete therapy activity tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of discharged patients before 1400 (Mon-Fri)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of programme validation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absorption of Acetaminophen as Indicated by Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration Acetaminophen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration of Acetaminophen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-rated plan/organize score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in parent-rated plan/organize score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Serum s100β levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Retention in the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-Reported Adherence to Inspiratory Muscle Training
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adverse Events and IMT Training Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of force under affected lower extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of blood and tissue microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Smart Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sane Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients who meet the eligibility criteria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients that withdraw due to loss of consent or are lost to follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Contraction analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with anti-pneumococcal immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postnatal outcome of fetuses
Endpoint domain: Mortality/survival
Primary endpoint: Patterns of treatment in mild asthma
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of Life (SF-36v2)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: amount of intra-operative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-vaccination COVID-19 cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Discharge Training Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Care Strength
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adherence with NIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric pain score at 30 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric pain score at 60 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCFA dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: interleukin-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 1,3-β-D-glucan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Therapeutic alliance scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported Tobacco Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with GNAS and KRAS mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Early morning stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of IBS patients experiencing clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Position of the margin of the restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar ridge horizontal net bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Observed Operational Taxonomic Unit (OTU) diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of exacerbation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of intraocular pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: holistic well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: prenatal attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postpartum physical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to diagnosis and treatment of postpartum complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in unmedicated DIOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC ratios of rongliflozin+rifampicin relative to rongliflozin alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax ratios of rongliflozin+rifampicin relative to rongliflozin alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC ratios of rongliflozin+probenecid relative to rongliflozin alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax ratios of rongliflozin+probenecid relative to rongliflozin alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Borg dyspnea scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of AI Model in Fracture Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progress to euvolemic target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in body composition (total and regional fat mass and fat free mass)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Histologic subtype classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Core symptoms of Borderline Personality Disorder (BPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wong Baker Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Fear Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thickness of fibrous cap of artery plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in lesion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: changes in hemorrhage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: changes in National Institutes of Health Stroke Scale (NIHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Digital Experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Brief Young Adult Alcohol Consequences Questionnaire (B-YAACQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Alcohol Use Disorder Identification Test (AUDIT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Rutgers Alcohol Problems Index (RAPI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severity of premenstrual symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: iTreg expansion capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Muscle quantitative index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of live birth
Endpoint domain: Mortality/survival
Primary endpoint: Increase in total exercise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-sufficiency
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: skill grade
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: information note
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Local and systemic safety assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Sleep Bruxism
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Unsolicited local and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Bulimia nervosa remission
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Differences of serum GLP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Differences of serum GIP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Differences of blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin dose over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glycemic values over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: WOMAC scale for osteoarthritis
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Cardiorespiratory fitness (VO2 max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective patient perception of skin
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in skin hydration levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in skin viscoelasticity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in skin surface topography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum dehydroepiandrosterone sulfate (DHEAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: follicle stimulating hormone (FSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: luteinizing hormone (LH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: estradiol (E2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gender-typed behavior
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Percentage of patients with MARS-5 Score ≥ 80%
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Minimum plasma drug concentration (Cmin) during pregnancy and postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum breastmilk drug concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma drug concentration (Cmin) during pregnancy and postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of MIS-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of invasive bacterial infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of viral infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Geometric mean titers (GMT) of neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroresponse Rate (SRR) of neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Grade of screw invasion into the pedicle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fruit and vegetables intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VRS-4 pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subretinal fluid regression ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central retinal thickness changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the concentration-time curve from 0 hours to 24 hours (AUC0-24h) of M1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed plasma exogenous insulin glargine concentration (Cmax) of M1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the Glucose infusion rate (GIR) -time curve from 0 hours to 24 hours (GIRAUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum GIR (GIRmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Plasma Concentration (Cmax,ss) of DWP16001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUCtau,ss) of DWP16001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax,ss) of DWC202010
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUCtau,ss) of DWC202010
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume and location analysis of physiological and standard CTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FC of genetic test results or family history of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CRM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality adjusted life year
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Institutionalization rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-Reported Foot and Ankle Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Endothelial count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Time Per Correctly Identified Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of esophageal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Skeletal Related Events (SREs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in SINS assessment at 180 days compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Back-specific Numeric Rating Scale for Pain (Back NRS) at 180 days compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Optimal Insulin Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Medication Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Between-day smallest real difference (SRD) for femoral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Between-day coefficient of variance (CV) for femoral blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vaccination status at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of history of locoregional
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of nephrocalcinosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24-item Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child Depression Rating Scale-Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to potassium rescue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child's eczema severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent's self-efficacy of eczema management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status